ClinicaliQ Trial Snapshot
- Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma — Recruiting • Phase I / Phase II • NCT04989803.
- Trial testing two new cell therapies (KITE-363 and KITE-753) for B-cell lymphoma that hasn't responded to standard treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma. Conditions: Relapsed and/or Refractory B-cell Lymphoma Interventions: Cyclophosphamide, Fludarabine, KITE-363, KITE-753 Lead Sponsor: Kite, A Gilead Company Planned Enrollment: 247 participants